Investor Newsletter
Investor Newsletter
Brisbane, June 20, 2018 AEST (ABN Newswire) - Oventus Medical Ltd (ASX:OVN) is pleased to provide a copy of its latest newsletter for investors.

Key highlights from the newsletter include:

- An overview of the initiatives underway to roll Oventus' technology out into the dental and sleep channels in Australia and the USA

- An introduction to new Oventus USA team members, including an interview with Robin Randolf, Vice President of Marketing and Operations for Oventus in North America

- A product, research and development (R&D) and clinical trials update; and

- A summary of Oventus' recent and forthcoming events

To view a copy of the newsletter, investors can visit the Investor News section on the Oventus website or copy and paste the following link into their web browser:

About the Oventus O2Vent airway technology

The Oventus O2Vent is an oral appliance device which brings the lower jaw forward (a process commonly referred to as mandibular advancement) and incorporates an opening to the oral cavity to allow breathing through the device airway, bypassing obstructions of the nose and soft palate, stabilising the tongue base and reducing airway collapsibility during sleep.

Further information can be found on our website:

To view the newsletter, please visit:

About Oventus Medical Ltd

Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2Vent(TM) is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

For more information on Oventus' Sleep Treatment Platform, please visit



Mr Neil Anderson
Managing Director and CEO
M: +61-403-003-475

Jane Lowe
IR Department
M: +61-411-117-774 or

Related Companies

Oventus Medical Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 59) (Last 30 Days: 228) (Since Published: 5079) 

Oventus Medical Ltd NEWS: RECENT VISITS (4983)